A pilot study of addition of amifostine to melphalan, carboplatin, etoposide, and cyclophosphamide with autologous hematopoietic stem cell transplantation in pediatric solid tumors - A pediatric blood and marrow transplant consortium study

Journal of Pediatric Hematology/Oncology

Volumn 30, Issue 3, 2008, Pages 204-209

  Ozkaynak, M Fevzi ^a   Sahdev, Indira ^b   Gross, Thomas G ^c   Levine, John E ^d   Cheerva, Alexandra C ^e   Richards, Michael K ^f   Rozans, Marta K ^g   Shaw, Peter J ^h   Kadota, Richard P ⁱ  

^a NEW YORK MEDICAL COLLEGE   (United States)

^b SCHNEIDER CHILDREN'S HOSPITAL   (United States)

^c NATIONWIDE CHILDREN S HOSPITAL   (United States)

^d UNIVERSITY OF MICHIGAN   (United States)

^e KOSAIR CHILDREN'S HOSPITAL   (United States)

^f Childrens Hospitals and Clinics of Minnesota   (United States)

^g ST CHRISTOPHER'S HOSPITAL FOR CHILDREN   (United States)

^h CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

ⁱ RADY CHILDREN'S HOSPITAL   (United States)

Author keywords

Amifostine; Autologous hematopoietic stem cell transplantation; Carboplatin; Cyclophosphamide; Etoposide; Melphalan; Pediatric solid tumors

Indexed keywords

ACICLOVIR; AMIFOSTINE; CALCIUM; CALCIUM CARBONATE; CALCIUM CHLORIDE; CALCIUM GLUBIONATE; CARBOPLATIN; CIMETIDINE; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DIPHENHYDRAMINE; ETOPOSIDE; FLUCONAZOLE; GRANULOCYTE COLONY STIMULATING FACTOR; MELPHALAN; NYSTATIN; ONDANSETRON; RANITIDINE; SODIUM CHLORIDE;

ACUTE KIDNEY FAILURE; ADOLESCENT; ADULT; ANAPLASTIC CARCINOMA; AREA UNDER THE CURVE; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BONE MARROW SUPPRESSION; CALCIUM BLOOD LEVEL; CANCER COMBINATION CHEMOTHERAPY; CENTRAL NERVOUS SYSTEM TUMOR; CHEMOTHERAPY INDUCED EMESIS; CHILD; CHILDHOOD CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DESMOPLASTIC SMALL ROUND CELL TUMOR; DRUG DOSE ESCALATION; DRUG DOSE REGIMEN; DRUG SAFETY; DRUG TOLERABILITY; ERYTHROCYTE TRANSFUSION; ESOPHAGITIS; EVENING DOSAGE; EWING SARCOMA; FEBRILE NEUTROPENIA; GASTRITIS; GERM CELL TUMOR; GLIOMA; GRAM NEGATIVE SEPSIS; HODGKIN DISEASE; HUMAN; HYPERTENSION; HYPOCALCEMIA; HYPOTENSION; INFECTION PREVENTION; LIVER VENOOCCLUSIVE DISEASE; LUNG EDEMA; MORNING DOSAGE; MUCOSA INFLAMMATION; MULTIPLE ORGAN FAILURE; MYCOSIS; MYOSARCOMA; NAUSEA; NEPHROBLASTOMA; NEUROBLASTOMA; NEUTROPENIA; OSTEOSARCOMA; OVARY TUMOR; PILOT STUDY; POSTOPERATIVE INFECTION; PRIORITY JOURNAL; RHABDOMYOSARCOMA; SEIZURE; SEPSIS; SOLID TUMOR; SYNOVIAL SARCOMA; THROMBOCYTE TRANSFUSION; UNSPECIFIED SIDE EFFECT; VIRUS PNEUMONIA;

ADOLESCENT; ADULT; AMIFOSTINE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW TRANSPLANTATION; BONE NEOPLASMS; CARBOPLATIN; CENTRAL NERVOUS SYSTEM NEOPLASMS; CHILD; CHILD, PRESCHOOL; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG TOXICITY; ETOPOSIDE; FEASIBILITY STUDIES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HODGKIN DISEASE; HUMANS; HYPOCALCEMIA; KIDNEY NEOPLASMS; MELPHALAN; NEOPLASMS; NEUROBLASTOMA; PILOT PROJECTS; RECURRENCE; RISK FACTORS; SARCOMA; TRANSPLANTATION, AUTOLOGOUS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; WILMS TUMOR;

EID: 41849090811     PISSN: 10774114     EISSN: 15363678     Source Type: Journal    
DOI: 10.1097/MPH.0b013e318162bd0c     Document Type: Article

References (42)

1. Matthay KK, Reynolds CP, Villablanca JG, et al. 13-cis retinoic acid after intensive consolidation therapy for neuroblastoma improves event-free survival: a randomized Children's Cancer Group Study. New Engl J Med. 1999;341:1097.
2. Philips GL, Reece DL. Clinical studies of autologous bone marrow transplantation in Hodgkin's disease. Clin Haematol. 1986;15:151-166.
3. Jagannath S, Armitage JO, Dicke KA, et al. Prognostic factors for response and survival after high-dose cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation for relapsed Hodgkin's disease. J Clin Oncol. 1989;7:179-185.
4. Carella AM, Congiu AM, Gaozza E, et al. High-dose chemotherapy with autologous bone marrow transplantation in 50 advanced resistant Hodgkin's disease patients: an Italian Group Report. J Clin Oncol. 1988;6:1411-1416.
5. Wheeler C, Antin JH, Churchill WH, et al. Cyclophosphamide, Carmustine and Etoposide with autologous bone marrow transplantation in refractory Hodgkin's disease and non-Hodgkin's lymphoma: a dose finding study. J Clin Oncol. 1990;8:648-656.
6. Bureo E, Ortega JJ, Munoz A, et al. Bone marrow transplantation in 46 pediatric patients with non-Hodgkin's lymphoma. Spanish Working Party for Bone Marrow Transplantation in Children. Bone Marrow Transplant. 1995;15:353.
7. Dunkel IJ, Boyett JM, Yates A, et al. High-dose carboplatin, thiotepa and etoposide with autologous stem-cell rescue for patients with recurrent medulloblastoma. Children's Cancer Group Study. J Clin Oncol. 1998;16:222-228.
8. Finlay J, August C, Packer R, et al. High dose multi-agent chemotherapy followed by bone marrow 'rescue' for malignant astrocytomas of childhood and adolescence. J Neurooncol. 1990;9:239-248.
9. Guruangan S, Dunkel IJ, Goldman S, et al. Myeloablative chemotherapy with autologous bone marrow rescue in young children with recurrent malignant brain tumors. J Clin Oncol. 1998; 16:2486-2493.
10. Garaventa A, Hartmann O, Bernard JL, et al. Autologous bone marrow transplantation for pediatric Wilms tumor: the experience of the European Bone Marrow Transplantation Solid Tumor Registry. Med Pediatr Oncol. 1994;22:11-14.
11. Kremens B, Gruhn B, Klingebiel T, et al. High-dose chemotherapy with autologous stem cell rescue in children with nephroblastoma. Bone Marrow Transplant. 2002;30:893-898.
12. De Giorgi U, Rosti G, Slavin S, et al. Salvage high-dose chemotherapy for children with extragonadal germ-cell tumours. Br J Cancer. 2005;93:412-417.
13. Meyers PA, Krailo MD, Ladanyi M, et al. High-dose melphalan, etoposide, total-body irradiation and autologous stem-cell reconstitution as consolidation therapy for high-risk Ewing's sarcoma does not improve prognosis. J Clin Oncol. 2001;19:2812-2820.
14. Ladenstein R, Hartman O, Pinkerton R, et al. A multivariate and matched pair analysis on high-risk Ewing tumor (ET) patients treated with megatherapy (MGT) and stem cell reinfusion (SCR) in Europe(abstract). Proc Am Soc Clin Oncol. 1999;18:2144..
15. Barker LM, Pendergrass TW, Sanders JE, et al. Survival after recurrence of Ewing's sarcoma family of tumors. J Clin Oncol. 2005;23:4354-4362.
16. Treskes M, Holwerda U, Klein I, et al. The chemical reactivity of the modulating agent WR-2721 (ethiofos) and its main metabolites with the antitumor agents cisplatin and carboplatin. Biochem Pharmacol. 1991;42:2125-2130.
17. Treskes M, Nijtmans LG, Fichtinger-Schepman AMJ, et al. Effects of the modulating agent WR-2721 and its main metabolites on the formation and stability of cisplatin-DNA adducts in vitro in comparison to the effects of thiosulfate and diethyldithiocarbanate. Biochem Pharmacol. 1992;43:1013-1019.
18. Millar JL, McElwain TJ, Clutterbuck RD, et al. The modification of melphalan toxicity in tumor bearing mice by S-2(3-aminmopropylamino)- ethylphosporothioic acid (WR-2721). Am J Clin Oncol. 1982;5:321-328.
19. Treskes M, van der Vijgh WJ. WR-2721 as a modulator of cisplatin and carboplatin induced side effects in comparison with other chemoprotective agents. A molecular approach. Cancer Chemother Pharmacol. 1993;33:93-106.
20. Valeriote F, Tolen S. Protection and potentiation of nitrogen mustard cytotoxicity by WR-2721. Cancer Res. 1982;42:4330-4331.
21. Treskes M, Boven E, Holwerda U, et al. Time dependence of the selective modulation of cisplatin-induced nephrotoxicity by WR-2721 in the mouse. Cancer Res. 1992;52:2257-2260.
22. Treskes M, Nijtmans L, Fichtinger-Schepman AMJ, et al. Cytostatic activity of cisplatin in the presence of WR-2721 and its thiol metabolite WR-1065 in OVCAR-3 human ovarian cancer cells as compared to V79 fibroblasts. Anticancer Res. 1992;12:2261-2266.
23. Glover D, Glick JH, Weiler C, et al. WR-2721 and high-dose cisplatin: an active combination in the treatment of metastatic melanoma. J Clin Oncol. 1987;5:574-578.
24. Glover D, Glick JH, Weiler C, et al. Phase I/II trials of WR-2721 and cis-platinum. Int J Radiat Oncol Biol Phys. 1986;12:1509-1512.
25. Glover D, Grabelsky S, Fox K, et al. Clinical trials of WR-2721 and cis-platinum. Int J Radiat Oncol Biol Phys. 1989;16:1201-1204.
26. Glick JH, Glover DJ, Weiler C, et al. Phase I clinical trials of WR-2721 with alkylating chemotherapy. Int J Radiat Oncol Biol Phys. 1982;3:575-580.
27. Grdina DJ, Sigdestad CP. Radiation protectors: the unexpected benefits. Drug Metab Rev. 1989;20:1342.
28. Adamson PC, Balis FM, Belasco JE, et al. A phase I trial of amifostine (WR-2721) and melphalan in children with refractory cancer. Cancer Res. 1995;55:4069-4072.
29. Fulda S, Oster W, Berthold F. Effects of WR-2721 (amifostine) and its metabolite WR-1065 on the antiproliferative activity of chemotherapeutic agents on neuroblastoma cells in vitro. Anticancer Drugs. 1997;8:34-41.
30. Fichtner I, Lemm M, Becker M, et al. Effects of amifostine (WR-2721, ethyol) on tumor growth and pharmacology of cytotoxic drugs in human xenotransplanted neuroblastomas. Anticancer Drugs. 1997;8:174-181.
31. Borsi JD, Csaki C, Ferenez T, et al. Administration of Ethyol (amifostine) to a child with medulloblastoma to ameliorate hematological toxicity of high dose carboplatin. Anticancer Drugs. 1996;7:121-126.
32. Borsi JD, Csaki C, Ferencz T, et al. Safety and efficacy of amifostine in children to prevent myelotoxicity of high-dose carboplatin: preliminary results of a cooperative phase I to II clinical trial. Proc Am Soc Clin Oncol. 1997;16:523a.
33. Fouladi M, Stempak D, Gammon J, et al. Phase I trial of a twicedaily regimen of amifostine with ifosfamide, carboplatin, and etoposide chemotherapy in children with refractory carcinoma. Cancer. 2001;92:914-923.
34. Phillips GL, Meisenberg B, Reece DE, et al. Amifostine and autologous hematopoietic stem cell support of escalating-dose melphalan: a phase I study. Biol Blood Marrow Transplant. 2004;10:473-483.
35. Thieblemont C, Dumontet C, Saad H, et al. Amifostine reduces mucosal damage after high-dose melphalan conditioning and autologous peripheral blood progenitor cell transplantation for patients with multiple myeloma. Bone Marrow Transplant. 2002;30:769-775.
36. 2 with amifostine cytoprotection and autologous hematopoietic stem cell support in non-Hodgkin and Hodgkin lymphoma. Bone Marrow Transplant. 2004;33:781-787.
37. Hwang WYK, Koh L-P, Ng HG, et al. A randomized trial of amifostine as a cytoprotectant for patients receiving myeloablative therapy for allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2004;34:51-56.
38. Renner S, Krumpelmann S, Bruchelt G, et al. Effect of amifostine on neuroblastoma during high dose chemotherapy: in vivo and in vitro investigations. Anticancer Res. 2000;20:4531-4538.
39. Fisher MJ, Lange BJ, Needle MN, et al. Amifostine for children with medulloblastoma treated with cisplatin-based chemotherapy. Pediatr Blood Cancer. 2004;43:780-784.
40. Bernstein ML, Devidas M, Lafreniere D, et al. Intensive therapy with growth factor support for patients with Ewing tumor metastatic at diagnosis: Pediatric Oncology Group/Children's Cancer Group Phase II Study 9457-a report from the Children's Oncology Group. J Clin Oncol. 2006;24:152-159.
41. Marina N, Chang KW, Malogolowkin M, et al. Amifostine does not protect against the ototoxicity of high-dose cisplatin combined with etoposide and bleomycin in pediatric germ-cell tumors: a Children's Oncology Group study. Cancer. 2005;104:841-847.
42. Petrilli AS, Oliveira DT, Ginani VC, et al. Use of amifostine in the therapy of osteosarcoma in children and adolescents. J Pediatr Hematol Oncol. 2002;24:188-191.